
Maroeska te Loo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/626195/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. Blood, 2014, 123, 2026-2033.	1.4	177
2	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-κB dependent up-regulation of IL-8 and MCP-11. Kidney International, 2002, 62, 846-856.	5.2	105
3	Prognostic Significance of Blasts in the Cerebrospinal Fluid Without Pleiocytosis or a Traumatic Lumbar Puncture in Children With Acute Lymphoblastic Leukemia: Experience of the Dutch Childhood Oncology Group. Journal of Clinical Oncology, 2006, 24, 2332-2336.	1.6	96
4	The role of pharmacogenetics in the treatment of osteosarcoma. Drug Discovery Today, 2016, 21, 1775-1786.	6.4	58
5	Polymorphisms and mutations of human TMPRSS6 in iron deficiency anemia. Blood Cells, Molecules, and Diseases, 2010, 44, 16-21.	1.4	56
6	Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia. Journal of Antimicrobial Chemotherapy, 2011, 66, 1853-1856.	3.0	56
7	Influence of Genetic Variants in TPMT and COMT Associated with Cisplatin Induced Hearing Loss in Patients with Cancer: Two New Cohorts and a Meta-Analysis Reveal Significant Heterogeneity between Cohorts. PLoS ONE, 2014, 9, e115869.	2.5	47
8	The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma. Oncotarget, 2014, 5, 12753-12768.	1.8	46
9	Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Pharmacogenetics and Genomics, 2016, 26, 243-247.	1.5	42
10	Decrease of thrombomodulin contributes to the procoagulant state of endothelium in hemolytic uremic syndrome. Pediatric Nephrology, 2003, 18, 1066-1068.	1.7	34
11	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clinical Cancer Research, 2015, 21, 3436-3441.	7.0	34
12	Age as prognostic factor in patients with osteosarcoma. Bone, 2011, 49, 1173-1177.	2.9	33
13	Survival Trends and Long-Term Toxicity in Pediatric Patients with Osteosarcoma. Sarcoma, 2012, 2012, 1-5.	1.3	33
14	Production of hemopexin by TNF-α stimulated human mesangial cells. Kidney International, 2003, 63, 1681-1686.	5.2	31
15	Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrology Dialysis Transplantation, 2007, 22, 749-755.	0.7	31
16	The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. Pharmacogenomics Journal, 2014, 14, 115-119.	2.0	27
17	Responseâ€guided chemotherapy for pediatric acute myeloid leukemia without hematopoietic stem cell transplantation in first complete remission: Results from protocol DB AMLâ€01. Pediatric Blood and Cancer, 2019, 66, e27605.	1.5	26
18	Vero Cytotoxin Binding to Polymorphonuclear Leukocytes among Households with Children with Hemolytic Uremic Syndrome. Journal of Infectious Diseases, 2001, 184, 446-450.	4.0	24

Maroeska te Loo

#	Article	IF	CITATIONS
19	TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial. BMC Pediatrics, 2017, 17, 122.	1.7	22
20	Serum Shiga toxin 2 values in patients during acute phase of diarrhoeaâ€associated haemolytic uraemic syndrome. Acta Paediatrica, International Journal of Paediatrics, 2015, 104, e564-8.	1.5	19
21	Pediatric Diamondâ€Blackfan anemia in the Netherlands: An overview of clinical characteristics and underlying molecular defects. European Journal of Haematology, 2018, 100, 163-170.	2.2	19
22	Efficacy and safety of recombinant <i>E. coli</i> asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group. Pediatric Blood and Cancer, 2018, 65, e27083.	1,5	18
23	Detection of Apoptosis in Kidney Biopsies of Patients with D+ Hemolytic Uremic Syndrome. Pediatric Research, 2001, 49, 413-416.	2.3	17
24	Shiga toxin-1 affects nitric oxide production by human glomerular endothelial and mesangial cells. Pediatric Nephrology, 2006, 21, 1815-1823.	1.7	15
25	The Effect of Flavoring Oral Rehydration Solution on its Composition and Palatability. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 545-548.	1.8	14
26	Taqman genotyping assays can be used on decalcified and paraffinâ€embedded tissue from patients with osteosarcoma. Pediatric Blood and Cancer, 2011, 56, 35-38.	1.5	14
27	High-Quality Genotyping Data from Formalin-Fixed, Paraffin-Embedded Tissue on the Drug Metabolizing Enzymes and Transporters Plus Array. Journal of Molecular Diagnostics, 2015, 17, 4-9.	2.8	14
28	Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients. Haematologica, 2017, 102, 552-561.	3.5	14
29	Independent development of lymphoid and histiocytic malignancies from a shared early precursor. Leukemia, 2016, 30, 955-958.	7.2	13
30	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. Blood, 2014, 124, 3027-3029.	1.4	12
31	Genetic Variants as Predictive Markers for Ototoxicity and Nephrotoxicity in Patients with Locally Advanced Head and Neck Cancer Treated with Cisplatin-Containing Chemoradiotherapy (The PRONE) Tj ETQq1	1 0 <i>3</i> .8431	.4 rgBT /Over
32	Is there a role for the <i>MTHFR</i> 677C>T and 1298A>C polymorphisms in methotrexate-induced liver toxicity?. Pharmacogenomics, 2014, 15, 1401-1403.	1.3	10
33	A novel Dutch mutation in <i>UNC13D</i> reveals an essential role of the C2B domain in munc13â€4 function. Pediatric Blood and Cancer, 2012, 58, 598-605.	1.5	7
34	Anticardiolipin antibodies in D+ hemolytic uremic syndrome. Pediatric Nephrology, 2002, 17, 1042-1046.	1.7	6
35	Rapid-growing Tumor of the Cheek Mimicking a Malignant Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, 113-115.	0.6	6
36	The role of germline variants in chemotherapy outcome in brain tumors: a systematic review of pharmacogenetic studies. Pharmacogenomics, 2017, 18, 501-513.	1.3	3

#	Article	IF	CITATIONS
37	Association of a genetic variant in the <i>ABCC2</i> gene with high methotrexate plasma concentrations in pediatric malignancies Journal of Clinical Oncology, 2010, 28, 9522-9522.	1.6	3
38	Genetic variants in <i>MDR1</i> and <i>CYP3A5</i> and vincristine toxicity in children with acute lymphoblastic leukemia Journal of Clinical Oncology, 2010, 28, 9526-9526.	1.6	1
39	No treatment related mortality in patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) in Dutch Childhood Oncology Group protocols ALL-7 and ALL-8. Journal of Clinical Oncology, 2008, 26, 10004-10004.	1.6	Ο
40	Relevance of germ-line genetic variations for treatment response in pediatric osteosarcoma patients Journal of Clinical Oncology, 2011, 29, 9518-9518.	1.6	0